Mezigdomide Plus Elranatamab Produces Significant Response in Early MELT-MM Analysis (Pharmacy Times) - Sep 23, 2026 - "All 13 evaluable patients responded, and 12 achieved CR or better. Among 8 patients with stringent CR and available minimal residual disease (MRD) results, 7 (87.5%) achieved MRD negativity. The median time to first response was 17 days, and median progression-free survival was not reached after a median follow-up of 10 months."
P1/2 data • Multiple Myeloma
|